Cargando…

Neoadjuvant chemotherapy followed by minimally invasive esophagectomy is safe and feasible for treatment of esophageal squamous cell carcinoma

BACKGROUND: The advantage of neoadjuvant chemotherapy (NAC) followed by open esophagectomy for treatment of esophageal squamous cell carcinoma has been widely recognized. However, the safety and feasibility of NAC for patients receiving minimally invasive esophagectomy (MIE) remain controversial. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Shaohua, Yan, Tiansheng, Liu, Dandan, Wang, Keyi, Wang, Jingdi, Song, Jintao, Wang, Tong, He, Wei, Bai, Jie, Jin, Liang, Chen, Xiaoxin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5792721/
https://www.ncbi.nlm.nih.gov/pubmed/29319236
http://dx.doi.org/10.1111/1759-7714.12590
_version_ 1783296795630108672
author Ma, Shaohua
Yan, Tiansheng
Liu, Dandan
Wang, Keyi
Wang, Jingdi
Song, Jintao
Wang, Tong
He, Wei
Bai, Jie
Jin, Liang
Chen, Xiaoxin
author_facet Ma, Shaohua
Yan, Tiansheng
Liu, Dandan
Wang, Keyi
Wang, Jingdi
Song, Jintao
Wang, Tong
He, Wei
Bai, Jie
Jin, Liang
Chen, Xiaoxin
author_sort Ma, Shaohua
collection PubMed
description BACKGROUND: The advantage of neoadjuvant chemotherapy (NAC) followed by open esophagectomy for treatment of esophageal squamous cell carcinoma has been widely recognized. However, the safety and feasibility of NAC for patients receiving minimally invasive esophagectomy (MIE) remain controversial. The purpose of this study was to evaluate the potential impact of prior neoadjuvant chemotherapy on the clinical outcome of MIE by comparing two groups of patients, MIE alone and NAC plus MIE. METHODS: From May 2013 to July 2017, 124 patients with esophageal squamous cell carcinoma underwent MIE in our department, with 57 cases receiving NAC plus MIE and 67 cases receiving MIE alone. Perioperative parameters and short‐term postoperative survival were compared between these two groups to evaluate the safety and feasibility of NAC given before MIE. RESULTS: The group with NAC plus MIE had slightly longer operating time, more blood loss, higher morbidity, increased chance of surgical intensive care unit stay, and longer surgical intensive care unit stay time than the group with MIE alone. However, there was no statistically significant difference between these two groups (P > 0.05). The number of lymph nodes harvested was similar in the two groups without significant difference (P > 0.05). The overall survival was not significantly different between these two groups either (P > 0.05), although before surgery the clinical stage of the group with NAC plus MIE was more advanced than the group with MIE alone. CONCLUSIONS: NAC followed by MIE is safe and feasible for treatment of esophageal squamous cell carcinoma. NAC does not negatively impact the therapeutic outcome of MIE.
format Online
Article
Text
id pubmed-5792721
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley & Sons Australia, Ltd
record_format MEDLINE/PubMed
spelling pubmed-57927212018-02-12 Neoadjuvant chemotherapy followed by minimally invasive esophagectomy is safe and feasible for treatment of esophageal squamous cell carcinoma Ma, Shaohua Yan, Tiansheng Liu, Dandan Wang, Keyi Wang, Jingdi Song, Jintao Wang, Tong He, Wei Bai, Jie Jin, Liang Chen, Xiaoxin Thorac Cancer Original Articles BACKGROUND: The advantage of neoadjuvant chemotherapy (NAC) followed by open esophagectomy for treatment of esophageal squamous cell carcinoma has been widely recognized. However, the safety and feasibility of NAC for patients receiving minimally invasive esophagectomy (MIE) remain controversial. The purpose of this study was to evaluate the potential impact of prior neoadjuvant chemotherapy on the clinical outcome of MIE by comparing two groups of patients, MIE alone and NAC plus MIE. METHODS: From May 2013 to July 2017, 124 patients with esophageal squamous cell carcinoma underwent MIE in our department, with 57 cases receiving NAC plus MIE and 67 cases receiving MIE alone. Perioperative parameters and short‐term postoperative survival were compared between these two groups to evaluate the safety and feasibility of NAC given before MIE. RESULTS: The group with NAC plus MIE had slightly longer operating time, more blood loss, higher morbidity, increased chance of surgical intensive care unit stay, and longer surgical intensive care unit stay time than the group with MIE alone. However, there was no statistically significant difference between these two groups (P > 0.05). The number of lymph nodes harvested was similar in the two groups without significant difference (P > 0.05). The overall survival was not significantly different between these two groups either (P > 0.05), although before surgery the clinical stage of the group with NAC plus MIE was more advanced than the group with MIE alone. CONCLUSIONS: NAC followed by MIE is safe and feasible for treatment of esophageal squamous cell carcinoma. NAC does not negatively impact the therapeutic outcome of MIE. John Wiley & Sons Australia, Ltd 2018-01-10 2018-02 /pmc/articles/PMC5792721/ /pubmed/29319236 http://dx.doi.org/10.1111/1759-7714.12590 Text en © 2018 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial (http://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Articles
Ma, Shaohua
Yan, Tiansheng
Liu, Dandan
Wang, Keyi
Wang, Jingdi
Song, Jintao
Wang, Tong
He, Wei
Bai, Jie
Jin, Liang
Chen, Xiaoxin
Neoadjuvant chemotherapy followed by minimally invasive esophagectomy is safe and feasible for treatment of esophageal squamous cell carcinoma
title Neoadjuvant chemotherapy followed by minimally invasive esophagectomy is safe and feasible for treatment of esophageal squamous cell carcinoma
title_full Neoadjuvant chemotherapy followed by minimally invasive esophagectomy is safe and feasible for treatment of esophageal squamous cell carcinoma
title_fullStr Neoadjuvant chemotherapy followed by minimally invasive esophagectomy is safe and feasible for treatment of esophageal squamous cell carcinoma
title_full_unstemmed Neoadjuvant chemotherapy followed by minimally invasive esophagectomy is safe and feasible for treatment of esophageal squamous cell carcinoma
title_short Neoadjuvant chemotherapy followed by minimally invasive esophagectomy is safe and feasible for treatment of esophageal squamous cell carcinoma
title_sort neoadjuvant chemotherapy followed by minimally invasive esophagectomy is safe and feasible for treatment of esophageal squamous cell carcinoma
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5792721/
https://www.ncbi.nlm.nih.gov/pubmed/29319236
http://dx.doi.org/10.1111/1759-7714.12590
work_keys_str_mv AT mashaohua neoadjuvantchemotherapyfollowedbyminimallyinvasiveesophagectomyissafeandfeasiblefortreatmentofesophagealsquamouscellcarcinoma
AT yantiansheng neoadjuvantchemotherapyfollowedbyminimallyinvasiveesophagectomyissafeandfeasiblefortreatmentofesophagealsquamouscellcarcinoma
AT liudandan neoadjuvantchemotherapyfollowedbyminimallyinvasiveesophagectomyissafeandfeasiblefortreatmentofesophagealsquamouscellcarcinoma
AT wangkeyi neoadjuvantchemotherapyfollowedbyminimallyinvasiveesophagectomyissafeandfeasiblefortreatmentofesophagealsquamouscellcarcinoma
AT wangjingdi neoadjuvantchemotherapyfollowedbyminimallyinvasiveesophagectomyissafeandfeasiblefortreatmentofesophagealsquamouscellcarcinoma
AT songjintao neoadjuvantchemotherapyfollowedbyminimallyinvasiveesophagectomyissafeandfeasiblefortreatmentofesophagealsquamouscellcarcinoma
AT wangtong neoadjuvantchemotherapyfollowedbyminimallyinvasiveesophagectomyissafeandfeasiblefortreatmentofesophagealsquamouscellcarcinoma
AT hewei neoadjuvantchemotherapyfollowedbyminimallyinvasiveesophagectomyissafeandfeasiblefortreatmentofesophagealsquamouscellcarcinoma
AT baijie neoadjuvantchemotherapyfollowedbyminimallyinvasiveesophagectomyissafeandfeasiblefortreatmentofesophagealsquamouscellcarcinoma
AT jinliang neoadjuvantchemotherapyfollowedbyminimallyinvasiveesophagectomyissafeandfeasiblefortreatmentofesophagealsquamouscellcarcinoma
AT chenxiaoxin neoadjuvantchemotherapyfollowedbyminimallyinvasiveesophagectomyissafeandfeasiblefortreatmentofesophagealsquamouscellcarcinoma